Cancer
12
Companies
18
Drug Programs
2
Phase 3
0
Upcoming PDUFAs
Celcuity
Revtorpyk
Sanofi
Sarclisa Escena
Merck
Merck-Moderna cancer vaccine
Cullinan Therapeutics
zipalertinib
BioNTech
BioNTech-Genentech personalized cancer vaccine
Novartis AG
GSK2110183 (afuresertib)
BioNTech
personalized mRNA cancer vaccine
Arbutus Biopharma Corp
TKM-080301
Krystal Biotech, Inc.
Opdualag
ACTUATE THERAPEUTICS, INC.
9-ING-41
Moderna
personalized cancer vaccine
Checkpoint Pharmaceuticals
KRAS inhibitors
Moderna
Moderna-Merck cancer vaccine
Merck
mRNA cancer vaccine
BioNTech
Cancer Vaccine
Moderna
Cancer Vaccine
Trethera
TRE-515
Scancell
cancer drug
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| CELC Celcuity | Revtorpyk | Approved | — | — | — |
| SNY Sanofi | Sarclisa Escena | Approved | — | — | — |
| MRK Merck | Merck-Moderna cancer vaccine | Phase 3 | — | — | — |
| TRAX Cullinan Therapeutics | zipalertinib | Phase 3 | — | — | — |
| BNTX BioNTech | BioNTech-Genentech personalized cancer vaccine | Phase 2 | — | — | — |
| NVS Novartis AG | GSK2110183 (afuresertib) | Phase 2 | — | — | — |
| BNTX BioNTech | personalized mRNA cancer vaccine | Phase 2 | — | — | — |
| ABUS Arbutus Biopharma Corp | TKM-080301 | Phase 2 | — | — | — |
| KRYS Krystal Biotech, Inc. | Opdualag | Phase 2 | — | — | — |
| ACTU ACTUATE THERAPEUTICS, INC. | 9-ING-41 | Phase 2 | — | — | — |
| MRNA Moderna | personalized cancer vaccine | — | — | — | — |
| CKPT Checkpoint Pharmaceuticals | KRAS inhibitors | — | — | — | — |
| MRNA Moderna | Moderna-Merck cancer vaccine | — | — | — | — |
| MRK Merck | mRNA cancer vaccine | — | — | — | — |
| BNTX BioNTech | Cancer Vaccine | — | — | — | — |
| MRNA Moderna | Cancer Vaccine | — | — | — | — |
| TRAX Trethera | TRE-515 | — | — | — | — |
| SCLP.L Scancell | cancer drug | — | — | — | — |
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.